In patients with MAGE-A3-positive surgically resected NSCLC, adjuvant treatment with the MAGE-A3 immunotherapeutic did not improve disease-free survival when compared to placebo, which showed 60.5 months (95% CI 57.2-not reached) for the MAGE-A3 arm and 57.9 months (55.7-not reached) for the placebo group (HR 1.02, 95% CI 0.89–1.18; p = 0.74). Here, MAGEA3 is linked to non-small cell lung carcinoma.